Sectors > Healthcare Sector > Biotechnology Industry
Revenue Growth
Revenues
Biotechnology Industry
Companies engaged in biotechnology research and development of biotechnology related goods and services. Includes a wide variety of firms applying biology to technology, medicine, and engineering.
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Asset Utilization
- Book Value
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE Ratio
- PEG Ratio
- Payout Ratio TTM Pro
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Asset Utilization
- Book Value
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE Ratio
- PEG Ratio
- Payout Ratio TTM Pro
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| XRM | 3.50 | -0.10 | -2.78% | 53.02M |
| XRIT | 5.54 | +0.00 | +0.00% | 477.05M |
| XRAY | 36.26 | -0.74 | -2.00% | 5.150B |
| XRA | 2.04 | +0.22 | +12.09% | 179.23M |
| WF | 27.54 | -0.51 | -1.83% | 7.398B |
| WEYS | 22.67 | -0.69 | -2.95% | 247.78M |
| WEX | 0.552 | +0.00 | +0.00% | 2.042M |
| WETF | 6.56 | -0.12 | -1.80% | 795.60M |
| WESTD | 0.1849 | -0.02 | -9.76% | |
| WEST | 0.1849 | -0.02 | -9.76% | 3.108M |
